Drugs / KB803
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07016750 | Jun 2025 → Dec 2026 expected | generalized dominant dystrophic epidermolysis bullosa, recessive dystrophic epidermolysis bullosa | Krystal Biotech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KB803 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07016750 ↗ |
| Route | Other | “ophthalmic administration” NCT07016750 ↗ |